Aptahem finalizes Part 1a of the FIH study for its lead candidate Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today the finalization of FIH (First In Human) Part 1a study.

This decision is based on the data of the extra analyses leading to a more complete understanding of Apta-1´s mechanism of action. The decision will potentially save time moving forward with the clinical development program. The Phase 1a study is a so called dubble blind study and analysis and compilation of the unblinded results will now commence. Aptahem will present preliminary data when available. The final study report will be sent to the Authorities. Aptahem is now planning for the next step in clinic for Apta-1.

The objectives with Part 1a of the study was to evaluate the safety and tolerability of Apta-1 in multiple doses.

CEO Mikael Lindstam comments:

”We are happy to have taken this decision. To finalize and report Part 1a of the study is an important milestone. Now, I´m looking forward to the continuation of the clinical development program of Apta-1.”

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: [email protected]

This contains such information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the above contact person for publication on 9 November 2023.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.